BOCG Frank Yang Chaired the Biotech Roundtable at the 25th Greater China Private Equity Summit

The 25th Greater China Private Equity Summit concluded successfully in Hong Kong on May 19, bringing together over 650 participants, with more than 60 speakers exploring industry trends and emerging opportunities across the region.

Frank Yang, Founding Partner and CEO of Blue Ocean Capital Group (“BOCG”), chaired the biotech roundtable, where leading global investment experts engaged in in-depth discussions on cutting-edge biotech developments and cross-border investment strategies.

As the global biotech sector undergoes rapid innovation and restructuring, panelists shared insights on cross-border investment trends, differentiated positioning, and the long-term industry outlook. The roundtable brought together experts from leading investment institutions and industry players to examine key challenges and frontier opportunities, offering practical perspectives on cross-border investment and industrial upgrading.

Key Discussion Topics

· Opportunities, challenges, and coordinated development pathways for biotech in the Greater Bay Area

· The impact of Hong Kong’s CMPR regulatory reform on local development and its international positioning

· Equity structure design and optimized listing pathways in Hong Kong and U.S. markets for biotech companies

· Implications of new U.S. rules on Chinese clinical data for NewCo formation, licensing, and investment

· Technological breakthroughs and investment prospects in brain-computer interfaces and AI-driven drug development

· Differentiated global investment strategies

‍

Frank Yang commented: “The global biotech landscape continues to evolve rapidly. With strengthening innovation capabilities, China has emerged as a high-growth hub and an innovation powerhouse in life sciences. Surging outbound licensing deals, a rebound in market financing, and strong industry performance are attracting investment from multinational corporations and global capital. Investors should take a long-term view to capture intrinsic industry value and advance cross-border collaboration.”

Frank Yang also highlighted that Greater Bay Area is one of the world’s most dynamic and promising life science innovation clusters, driven by a vibrant innovation ecosystem, complementary strengths among Hong Kong, Shenzhen, and neighboring cities, strong fundamental research, and supportive policies—including an independent CMPR review system,  increasing R&D investment, and capital market reforms.

As a life science focused investor with “Global Horison, China Angle” , BOCG has been empowering innnovaiton with investments,  striving to bridge the gap between Chinese and international innovation, and  will continue to focus on cutting-edge breakthrough in life science with a specific emphasis on brain science and BCI, while enriching portfolio companies growth and  deepening cross-border industrial and  investment cooperation.